Provectus Appoints Heather Raines, CPA as Chief Financial Officer
March 25, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously...
Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
March 21, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
February 12, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
December 06, 2018 08:30 ET
|
Provectus Biopharmaceuticals Inc.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
November 12, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
November 05, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
September 18, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
September 11, 2018 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...